Caribou Biosciences, Inc.
Clinical-stage biopharma developing genome-edited allogeneic cell therapies.
CRBU | US
Overview
Corporate Details
- ISIN(s):
- US1420381089
- LEI:
- Country:
- United States of America
- Address:
- 2929 7TH STREET, SUITE 105, 94710 BERKELEY
- Website:
- https://www.cariboubio.com/
- Sector:
- Manufacturing
Description
Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative, genome-edited allogeneic cell therapies. The company leverages its proprietary, next-generation CRISPR platform, chRDNA (CRISPR hybrid RNA-DNA) technology, to achieve superior specificity and precision in complex genome editing. Its primary focus is on creating 'off-the-shelf' CAR-T cell therapies for patients with hematologic malignancies and solid tumors. A key component of its strategy is 'armoring' these therapies through multiple genome-editing techniques, such as checkpoint disruption and immune cloaking, to enhance their persistence and anti-tumor activity.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Caribou Biosciences, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Caribou Biosciences, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Caribou Biosciences, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
